Covid19

Infectious Diseases
52
Pipeline Programs
30
Companies
50
Clinical Trials
1 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
10
5
15
4
14
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
735%
Small Molecule
630%
Monoclonal Antibody
525%
RNA Therapeutic
15%
Peptide
15%
+ 54 programs with unclassified modality

On Market (3)

Approved therapies currently available

Insmed
BRINSUPRIApproved
brensocatib
Insmed
oral2025
Rigel Pharmaceuticals
TAVALISSEApproved
fostamatinib
Rigel Pharmaceuticals
oral2018
GS
VEKLURYApproved
remdesivir
Gilead Sciences
SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC]intravenous2020

Competitive Landscape

53 companies ranked by most advanced pipeline stage

GS
3 programs
1
1
RemdesivirPhase 3Small Molecule1 trial
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure DevelopmentN/A1 trial
Real World Study of COVID-19 in a Flyover RegionN/A1 trial
Active Trials
NCT04956445Unknown2,000Est. Mar 2025
NCT04962347Completed1,800Est. Oct 2022
NCT06729593Completed87Est. Nov 2022
Insmed
InsmedBRIDGEWATER, NJ
1 program
1
1
BrensocatibPhase 31 trial
Active Trials
NCT04817332CompletedEst. Feb 2021
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program
1
1
FostamatinibPhase 3Small Molecule1 trial
Active Trials
NCT04629703CompletedEst. Sep 2022
Sanofi
SanofiPARIS, France
1 program
1
COVID-19 vaccine PfizerPhase 4Vaccine1 trial
Active Trials
NCT05047718Completed54Est. Feb 2023
Vir Biotechnology
8 programs
2
1
1
2
LY3819253Phase 3
sotrovimabPhase 3Monoclonal Antibody1 trial
VIR-7831Phase 2/31 trial
SotrovimabPhase 2Monoclonal Antibody1 trial
sotrovimabPhase 1Monoclonal Antibody1 trial
+3 more programs
Active Trials
NCT05235347No Longer Available
NCT04988152Completed48Est. Dec 2021
NCT05280717Terminated316Est. Nov 2023
+3 more trials
Pfizer
PfizerNEW YORK, NY
3 programs
2
LY3819253Phase 3
Tofacitinib 10 mgPhase 31 trial
Laboratory and instrumental examinationN/A1 trial
Active Trials
NCT04871789Unknown200Est. Jun 2021
NCT04469114Completed289Est. Jan 2021
Molecular Partners
2 programs
1
1
LY3819253Phase 31 trial
ensovibepPhase 21 trial
Active Trials
NCT04834856Completed12Est. Aug 2021
NCT04501978Completed2,753Est. Jul 2023
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of carePhase 31 trial
Active Trials
NCT04410328Completed98Est. Oct 2021
Appili Therapeutics
1 program
1
FavipiravirPhase 3Small Molecule1 trial
Active Trials
NCT04600895Completed1,187Est. Oct 2021
Allergy Therapeutics
1 program
1
LY3819253Phase 3
Brii Biosciences
Brii BiosciencesCA - San Mateo
1 program
1
LY3819253Phase 3
Verona Pharma
1 program
1
Prasugrel Hydrochloride 10 MG Oral TabletPhase 31 trial
Active Trials
NCT04445623Unknown128Est. Jan 2021
Bayer
BayerLEVERKUSEN, Germany
1 program
1
Rivaroxaban 10 MGPhase 31 trial
Active Trials
NCT04662684Completed320Est. Aug 2021
United Therapeutics
2 programs
1
1
NiclosamidePhase 2/31 trial
SargramostimPhase 21 trial
Active Trials
NCT04707664Completed600Est. Jan 2022
NCT04870333Completed2,240Est. Apr 2025
C
CureVacGermany - Tübingen
1 program
1
CVnCoVPhase 2/31 trial
Active Trials
NCT04652102CompletedEst. Jun 2022
Axiom
AxiomCA - San Francisco
1 program
1
Shampoo and salinePhase 2/31 trial
Active Trials
NCT04802408Active Not RecruitingEst. May 2026
Alliance Pharmaceuticals
3 programs
1
1
N-acetylcysteinePhase 23 trials
CYP-001Phase 11 trial
COVID-19 STAndard of Care in Sub-Saharan AfricaN/A1 trial
Active Trials
NCT04885543Completed2,495Est. Mar 2021
NCT04537351Completed14Est. May 2022
NCT05074121Unknown200Est. Feb 2025
+2 more trials
Heidelberg Pharma
2 programs
1
BBIBP-CorV - Inactivated SARS-CoV-2 vaccinePhase 2Vaccine1 trial
Multicenter CTS Pre-and Post-Transplantation Covid-19 Serum StudiesN/A1 trial
Active Trials
NCT04694573Unknown600Est. Dec 2022
NCT04998240Unknown360Est. Feb 2024
Swedish Orphan Biovitrum
1 program
1
AnakinraPhase 21 trial
Active Trials
NCT04603742WithdrawnEst. Sep 2022
Vera Therapeutics
Vera TherapeuticsBRISBANE, CA
1 program
1
Analogs, Prostaglandin E1Phase 21 trial
Active Trials
NCT04536363WithdrawnEst. Dec 2020
Capricor Therapeutics
1 program
1
CAP-1002Phase 21 trial
Active Trials
NCT04623671Completed55Est. Feb 2022
Clene
CleneSALT LAKE CITY, UT
1 program
1
CNM-ZnAgPhase 21 trial
Active Trials
NCT04610138CompletedEst. Oct 2022
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
DefibrotidePhase 2Peptide1 trial
Active Trials
NCT04652115Recruiting42Est. Mar 2025
GC Biopharma
1 program
1
GC5131Phase 21 trial
Active Trials
NCT04555148CompletedEst. Apr 2021
Angel Pharmaceuticals
1 program
1
Hyperbaric OxygenPhase 21 trial
Active Trials
NCT04477954TerminatedEst. Dec 2020
Ionis Pharmaceuticals
1 program
1
ISIS 721744Phase 21 trial
Active Trials
NCT04549922Completed111Est. Dec 2021
AS
1 program
1
Masitinib MesylatePhase 21 trial
Active Trials
NCT05047783UnknownEst. Dec 2023
Biotest Pharmaceuticals
1 program
1
TrimodulinPhase 21 trial
Active Trials
NCT04576728CompletedEst. Jun 2021
ImmunityBio
4 programs
2
2
hAd5-S-Fusion+N-ETSD vaccinePhase 1/2Vaccine1 trial
hAd5-S-Fusion+N-ETSD vaccinePhase 1/2Vaccine1 trial
hAd5-S-Fusion+N-ETSDPhase 11 trial
hAd5-S-Fusion+N-ETSD vaccinePhase 1Vaccine1 trial
Active Trials
NCT04732468Terminated28Est. Jan 2023
NCT04710303Completed41Est. Aug 2022
NCT04845191Withdrawn0Est. Dec 2021
+1 more trials
Direct Biologics
2 programs
1
Bone Marrow Mesenchymal Stem Cell Derived Extracellular VesiclesPhase 1/21 trial
ExoFloN/A1 trial
Active Trials
NCT04657458No Longer Available
NCT05116761WithdrawnEst. Dec 2024

+23 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiCOVID-19 vaccine Pfizer
Vir Biotechnologysotrovimab
Gilead SciencesRemdesivir
Rigel PharmaceuticalsFostamatinib
Appili TherapeuticsFavipiravir
Boehringer IngelheimDipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care
BayerRivaroxaban 10 MG
PfizerTofacitinib 10 mg
Molecular PartnersLY3819253
Verona PharmaPrasugrel Hydrochloride 10 MG Oral Tablet
InsmedBrensocatib
AxiomShampoo and saline
United TherapeuticsNiclosamide
CureVacCVnCoV
Vir BiotechnologyVIR-7831

Showing 15 of 48 trials with date data

Clinical Trials (50)

Total enrollment: 13,597 patients across 50 trials

NCT05047718SanofiCOVID-19 vaccine Pfizer

Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19

Start: Oct 2021Est. completion: Feb 202354 patients
Phase 4Completed
NCT04913675Vir Biotechnologysotrovimab

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

Start: Jun 2021Est. completion: Mar 20231,065 patients
Phase 3Terminated
NCT06729593Gilead SciencesRemdesivir

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

Start: Apr 2021Est. completion: Nov 202287 patients
Phase 3Completed
NCT04629703Rigel PharmaceuticalsFostamatinib

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

Start: Mar 2021Est. completion: Sep 2022
Phase 3Completed
NCT04600895Appili TherapeuticsFavipiravir

The Prevent Severe COVID-19 (PRESECO) Study

Start: Nov 2020Est. completion: Oct 20211,187 patients
Phase 3Completed
NCT04410328Boehringer IngelheimDipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care

Aggrenox To Treat Acute Covid-19

Start: Oct 2020Est. completion: Oct 202198 patients
Phase 3Completed
NCT04662684BayerRivaroxaban 10 MG

Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial

Start: Oct 2020Est. completion: Aug 2021320 patients
Phase 3Completed
NCT04469114PfizerTofacitinib 10 mg

Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia

Start: Sep 2020Est. completion: Jan 2021289 patients
Phase 3Completed
NCT04501978Molecular PartnersLY3819253

ACTIV-3: Therapeutics for Inpatients With COVID-19

Start: Aug 2020Est. completion: Jul 20232,753 patients
Phase 3Completed
NCT04445623Verona PharmaPrasugrel Hydrochloride 10 MG Oral Tablet

Prasugrel in Severe COVID-19 Pneumonia

Start: Jul 2020Est. completion: Jan 2021128 patients
Phase 3Unknown
NCT04817332InsmedBrensocatib

STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19

Start: Jun 2020Est. completion: Feb 2021
Phase 3Completed
NCT04802408AxiomShampoo and saline

SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial

Start: Oct 2021Est. completion: May 2026
Phase 2/3Active Not Recruiting
NCT04870333United TherapeuticsNiclosamide

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

Start: Feb 2021Est. completion: Apr 20252,240 patients
Phase 2/3Completed
NCT04652102CureVacCVnCoV

A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older

Start: Dec 2020Est. completion: Jun 2022
Phase 2/3Completed
NCT04545060Vir BiotechnologyVIR-7831

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

Start: Aug 2020Est. completion: Sep 20211,057 patients
Phase 2/3Completed
NCT05074121Alliance PharmaceuticalsN-acetylcysteine

NAC for Attenuation of COVID-19 Symptomatology

Start: Mar 2024Est. completion: Feb 2025200 patients
Phase 2Unknown
NCT04998240Heidelberg PharmaBBIBP-CorV - Inactivated SARS-CoV-2 vaccine

Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines

Start: Dec 2021Est. completion: Feb 2024360 patients
Phase 2Unknown
NCT04603742Swedish Orphan BiovitrumAnakinra

Anakinra, COVID-19, Cytokine Storm

Start: Dec 2021Est. completion: Sep 2022
Phase 2Withdrawn
NCT05047783AB ScienceMasitinib Mesylate

Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

Start: Nov 2021Est. completion: Dec 2023
Phase 2Unknown
NCT04610138CleneCNM-ZnAg

Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants

Start: Jun 2021Est. completion: Oct 2022
Phase 2Completed
NCT04707664United TherapeuticsSargramostim

Sargramostim Use in COVID-19 to Recover Patient Health

Start: Apr 2021Est. completion: Jan 2022600 patients
Phase 2Completed
NCT04834856Molecular Partnersensovibep

Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients

Start: Apr 2021Est. completion: Aug 202112 patients
Phase 2Completed
NCT04779879Vir BiotechnologySotrovimab

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

Start: Feb 2021Est. completion: Apr 2022354 patients
Phase 2Completed
NCT04652115Jazz PharmaceuticalsDefibrotide

Defibrotide for the Treatment of Severe COVID-19

Start: Jan 2021Est. completion: Mar 202542 patients
Phase 2Recruiting
NCT04536363Vera TherapeuticsAnalogs, Prostaglandin E1

Cri Analog PG1 Effectiveness and Safety in Covid-19

Start: Dec 2020Est. completion: Dec 2020
Phase 2Withdrawn
NCT04623671Capricor TherapeuticsCAP-1002

Intravenous Infusion of CAP-1002 in Patients With COVID-19

Start: Nov 2020Est. completion: Feb 202255 patients
Phase 2Completed
NCT04549922Ionis PharmaceuticalsISIS 721744

Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19

Start: Oct 2020Est. completion: Dec 2021111 patients
Phase 2Completed
NCT04576728Biotest PharmaceuticalsTrimodulin

Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19

Start: Oct 2020Est. completion: Jun 2021
Phase 2Completed
NCT04419025Alliance PharmaceuticalsN-acetylcysteine

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

Start: Sep 2020Est. completion: May 2021165 patients
Phase 2Completed
NCT04555148GC BiopharmaGC5131

COVIDIG (COVID-19 Hyper-ImmunoGlobulin)

Start: Sep 2020Est. completion: Apr 2021
Phase 2Completed
NCT04477954Angel PharmaceuticalsHyperbaric Oxygen

Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia

Start: Jul 2020Est. completion: Dec 2020
Phase 2Terminated
NCT00453180Alliance PharmaceuticalsN-acetylcysteine

A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders

Start: Mar 2007Est. completion: Nov 200931 patients
Phase 2Completed
NCT05116761Direct BiologicsBone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles

ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome

Start: Nov 2024Est. completion: Dec 2024
Phase 1/2Withdrawn
NCT04845191ImmunityBiohAd5-S-Fusion+N-ETSD vaccine

COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines

Start: Dec 2021Est. completion: Dec 20210
Phase 1/2Withdrawn
NCT04843722ImmunityBiohAd5-S-Fusion+N-ETSD vaccine

COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines

Start: Dec 2021Est. completion: Dec 20210
Phase 1/2Withdrawn
NCT04821674Daiichi SankyoDS-5670a

Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects

Start: Mar 2021Est. completion: Jul 2022142 patients
Phase 1/2Completed
NCT04539795Mereo BioPharmaAlvelestat

COVID-19 Study of Safety and Tolerability of Alvelestat

Start: Jan 2021Est. completion: Oct 2021
Phase 1/2Completed
NCT05280717Vir Biotechnologysotrovimab

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

Start: Mar 2022Est. completion: Nov 2023316 patients
Phase 1Terminated
NCT04765449Tevogen BioCytotoxic T Lymphocytes

Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

Start: Sep 2021Est. completion: Jan 2023
Phase 1Completed
NCT04988152Vir Biotechnologysotrovimab

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

Start: Jul 2021Est. completion: Dec 202148 patients
Phase 1Completed
NCT04356677Bausch Health50 mg/mL Virazole

Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2

Start: May 2021Est. completion: Aug 2021
Phase 1Withdrawn
NCT04773665VBI VaccinesVBI-2902a

Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a

Start: Mar 2021Est. completion: Nov 2022
Phase 1Completed
NCT04710303ImmunityBiohAd5-S-Fusion+N-ETSD vaccine

COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults

Start: Mar 2021Est. completion: Aug 202241 patients
Phase 1Completed
NCT04732468ImmunityBiohAd5-S-Fusion+N-ETSD

COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

Start: Feb 2021Est. completion: Jan 202328 patients
Phase 1Terminated
NCT04551768Bausch Health50 mg/mL Virazole

Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19

Start: Feb 2021Est. completion: Aug 2021
Phase 1Completed
NCT04563702VaxartVXA-CoV2-1

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

Start: Sep 2020Est. completion: Oct 2021
Phase 1Completed
NCT04537351Alliance PharmaceuticalsCYP-001

The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause

Start: Aug 2020Est. completion: May 202214 patients
Phase 1Completed
NCT05235347Vir BiotechnologySotrovimab

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

N/ANo Longer Available
NCT04657458Direct BiologicsExoFlo

Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS

N/ANo Longer Available
NCT04962347Gilead SciencesReal World Study of COVID-19 in a Flyover Region

Real World Study of COVID-19 in a Flyover Region

Start: Oct 2021Est. completion: Oct 20221,800 patients
N/ACompleted

Related Jobs in Infectious Diseases

Executive Director, Global Medical Expert HIV Prevention - GMA Virology & Inflammation

Gilead Sciences
United States - Field
17h ago
$317K - $411K/yr

Sr. Engineer, Process Systems (Contract)

VaxCyte
Visp, Valais, Switzerland
20h ago

Director, Health Economics & Outcomes Research (HEOR)

VaxCyte
San Carlos, California, United States
22h ago
$242K - $282K/yr

Director U.S. Meningococcal Marketing

Pfizer
United States - New York - New York City
Yesterday
$177K - $294K/yr

Senior Manager, Contract Account Performance Specialist, Contract Strategy

Pfizer
Remote
Yesterday
$124K - $207K/yr

Scientist, Computational Vaccine Design

Metaphore Biotechnologies
Cambridge, MA USA
3d ago
$115K - $165K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

14 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 13,597 patients
30 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)HIV Infection(75)